VRTX vs MRNA — Key Metrics
| Metric | VRTX (VERTEX PHARMACEUTICALS INC) | MRNA (MODERNA INC) |
|---|---|---|
| Price | 522.81 | 192.57 |
| Market Cap | 132.51 Billion | 76.88 Billion |
| P/E (TTM) | 30.17 | -24.1 |
| P/B (Quarterly) | 5.992 | 3.237 |
| P/S (TTM) | 10.53 | 34.51 |
| Net Profit Margin (TTM) | 35.0 | -141.4 |
| Gross Margin (TTM) | 86.0 | 23.4 |
| ROE (TTM) | 23.3 | -39.2 |
| Revenue Growth YoY (TTM) | None | None |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
VRTX · VERTEX PHARMACEUTICALS INC
Outperform
MRNA · MODERNA INC
Greatly Underperform
Recommendation Summary
Stock VRTX is projected to outperform the market, stock MRNA is projected to greatly underperform the market. Upfront Recommendation: VRTX.
Financial Metrics
Prices delayed ~15 min
| VRTX | Metrics | MRNA |
|---|---|---|
| $522.81 | Price | $192.57 |
| — | Market Capitalization | — |
| 10.53 | Price to Sales | 34.51 |
| 12.24 | Price to Gross Profit | 147.56 |
| 33.92 | Price to R&D | 26.73 |
| 10.56 | Price to Current Assets | 13.22 |